C. Birbara

7.1k total citations · 4 hit papers
43 papers, 5.5k citations indexed

About

C. Birbara is a scholar working on Rheumatology, Pharmacology and Hematology. According to data from OpenAlex, C. Birbara has authored 43 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 14 papers in Pharmacology and 11 papers in Hematology. Recurrent topics in C. Birbara's work include Rheumatoid Arthritis Research and Therapies (16 papers), Autoimmune and Inflammatory Disorders Research (11 papers) and Spondyloarthritis Studies and Treatments (10 papers). C. Birbara is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Autoimmune and Inflammatory Disorders Research (11 papers) and Spondyloarthritis Studies and Treatments (10 papers). C. Birbara collaborates with scholars based in United States, United Kingdom and Canada. C. Birbara's co-authors include Daniel E. Furst, Steven Fischkoff, Elliot Chartash, Michael H. Weisman, Edward Keystone, Michael E. Weinblatt, Larry W. Moreland, Michael Schiff, M. Brown and Mike D. Smith and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Pain.

In The Last Decade

C. Birbara

43 papers receiving 5.3k citations

Hit Papers

Adalimumab, a fully human... 2003 2026 2010 2018 2003 2005 2005 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    2003 1.4k citations Michael E. Weinblatt, Edward Keystone et al. Arthritis & Rheumatism profile →
  2. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
    2005 920 citations Mark C. Genovese, Jean‐Claude Becker et al. New England Journal of Medicine profile →
  3. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    2005 553 citations Christian Antoni, Gerald G. Krueger et al. Annals of the Rheumatic Diseases profile →
  4. Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
    2010 499 citations Nancy E. Lane, Thomas J. Schnitzer et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
C. Birbara 3.8k 1.9k 1.8k 531 529 43 5.5k
Bruce Kirkham 4.1k 1.1× 3.9k 2.0× 2.1k 1.2× 206 0.4× 246 0.5× 143 7.2k
Raimón Sanmartí 3.6k 1.0× 1.6k 0.8× 1.3k 0.7× 416 0.8× 127 0.2× 263 5.3k
Alain Cantagrel 5.3k 1.4× 2.0k 1.1× 1.9k 1.1× 861 1.6× 141 0.3× 202 7.5k
Juan D. Cañete 3.8k 1.0× 2.7k 1.4× 1.5k 0.8× 363 0.7× 128 0.2× 218 6.0k
Maya H Buch 3.9k 1.0× 1.7k 0.9× 1.4k 0.8× 996 1.9× 130 0.2× 211 6.4k
Mary Chester Wasko 3.4k 0.9× 976 0.5× 1.2k 0.7× 606 1.1× 121 0.2× 64 5.0k
Mahboob U. Rahman 3.8k 1.0× 1.4k 0.7× 1.6k 0.9× 912 1.7× 121 0.2× 85 5.8k
L B van de Putte 3.5k 0.9× 1.2k 0.6× 969 0.5× 320 0.6× 193 0.4× 79 5.2k
Giovanni Lapadula 2.1k 0.6× 1.0k 0.5× 628 0.4× 236 0.4× 355 0.7× 191 4.5k
Jürgen Rech 3.7k 1.0× 2.5k 1.3× 1.2k 0.7× 768 1.4× 105 0.2× 187 7.0k

Countries citing papers authored by C. Birbara

Since Specialization
Citations

This map shows the geographic impact of C. Birbara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Birbara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Birbara more than expected).

Fields of papers citing papers by C. Birbara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Birbara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Birbara. The network helps show where C. Birbara may publish in the future.

Co-authorship network of co-authors of C. Birbara

This figure shows the co-authorship network connecting the top 25 collaborators of C. Birbara. A scholar is included among the top collaborators of C. Birbara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Birbara. C. Birbara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gottlieb, Alice B., Kim Papp, C. Birbara, et al.. (2018). Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. Journal of the American Academy of Dermatology. 79(3). 593–595. 5 indexed citations
2.
Birbara, C., Eugene J Dabezies, Aimee Burr, et al.. (2018). Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. Journal of Pain Research. Volume 11. 151–164. 28 indexed citations
3.
Edwards, Christopher J, Francisco J. Blanco, Jeffrey Crowley, et al.. (2016). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Annals of the Rheumatic Diseases. 75(6). 1065–1073. 215 indexed citations
4.
5.
Doyle, Mittie K., Mahboob U. Rahman, Bart Frederick, et al.. (2013). Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Lara D. Veeken. 52(7). 1214–1219. 37 indexed citations
6.
Katz, Nathaniel P., David Borenstein, C. Birbara, et al.. (2012). Response to letter by Ackermann. Pain. 153(5). 1129–1131. 2 indexed citations
7.
Schnitzer, Thomas J., Nancy E. Lane, C. Birbara, et al.. (2011). Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis and Cartilage. 19(6). 639–646. 89 indexed citations
8.
Katz, Nathaniel P., David Borenstein, C. Birbara, et al.. (2011). Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 152(10). 2248–2258. 183 indexed citations
9.
Lane, Nancy E., Thomas J. Schnitzer, C. Birbara, et al.. (2010). Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee. New England Journal of Medicine. 363(16). 1521–1531. 499 indexed citations breakdown →
10.
Mease, Philip J., P A Ory, John T. Sharp, et al.. (2008). Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Annals of the Rheumatic Diseases. 68(5). 702–709. 214 indexed citations
11.
Heijde, Désirée van der, Arthur Kavanaugh, Dafna D. Gladman, et al.. (2007). Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis & Rheumatism. 56(8). 2698–2707. 140 indexed citations
12.
Kavanaugh, Arthur, Gerald G. Krueger, Anna Beutler, et al.. (2006). Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Annals of the Rheumatic Diseases. 66(4). 498–505. 155 indexed citations
13.
Birbara, C., Gary Ruoff, Eric Sheldon, et al.. (2005). Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current Medical Research and Opinion. 22(1). 199–210. 20 indexed citations
14.
Genovese, Mark C., Jean‐Claude Becker, Michael Schiff, et al.. (2005). Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. New England Journal of Medicine. 353(11). 1114–1123. 920 indexed citations breakdown →
15.
Ollendorf, Daniel A., Elena Massarotti, C. Birbara, & Somali M. Burgess. (2005). Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients With Rheumatoid Arthritis. Journal of Managed Care Pharmacy. 11(5). 383–393. 32 indexed citations
16.
17.
Weinblatt, Michael E., Edward Keystone, Daniel E. Furst, et al.. (2003). Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis & Rheumatism. 48(1). 35–45. 1413 indexed citations breakdown →
18.
Birbara, C., Jeffrey R. Breiter, Carlos Perdomo, & William F. Hahne. (2000). Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. European Journal of Gastroenterology & Hepatology. 12(8). 889–897. 29 indexed citations
19.
Breiter, Jeffrey R., C. Birbara, Robert Niecestro, Carolina M. Perdomo, & William F. Hahne. (1999). Rabeprazole prevents recurrence of pathology and symptoms in patients with healed erosive or ulcerative gastroesophageal reflux disease. 2. 128. 4 indexed citations
20.
Buckler, Helen, William D. Fraser, D. J. Hosking, et al.. (1999). Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study. Bone. 24(5). 81S–85S. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce Kirkham Breakdown of academic impact, for papers by Raimón Sanmartí Breakdown of academic impact, for papers by Alain Cantagrel Breakdown of academic impact, for papers by Juan D. Cañete Breakdown of academic impact, for papers by Maya H Buch Breakdown of academic impact, for papers by Mary Chester Wasko Breakdown of academic impact, for papers by Mahboob U. Rahman Breakdown of academic impact, for papers by L B van de Putte Breakdown of academic impact, for papers by Giovanni Lapadula Breakdown of academic impact, for papers by Jürgen Rech
Rankless by CCL
2026